Overview
Lobbying Costs
75,000€
Financial year: Jan 2020 - Dec 2020
Lobbyists (Full time equivalent)
0.25 Fte (1)
Lobbyists with EP accreditation
0
High-level Commission meetings
7
Lobbying Costs over the years
-
Info
Illumina, Inc.
EU Transparency Register
547949121038-83 First registered on 11 Mar 2016
Goals / Remit
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Main EU files targeted
Illumina follows policy and legislative developments related to genomics, agri-genomics, public health, animal health, agriculture, forensics, biotechnology, data protection, science, and research policies. In particular, Illumina follows the discussions on the proposal for a EU Health Data Space and developments relating to the Regulations on medical devices and In-vitro diagnostics. It also engages in policy and regulatory initiatives relating to research and innovation in the EU, including more generally developments relating to EU research programs, with a focus on genomics research.
Address
Head Office
5200 Illumina Way
San Diego
UNITED STATES -
People
Total lobbyists declared
1
Employment time Lobbyists 25% 1 Lobbyists (Full time equivalent)
0.25
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 08 Mar 2021
Name Start date End Date Marie Helene FANDEL 18 Oct 2023 17 Oct 2024 Federico PISANI 17 Aug 2023 16 Aug 2024 Ms Marie Helene FANDEL 18 Oct 2023 15 Apr 2024 Mr Federico PISANI 17 Aug 2023 15 Apr 2024 Mr Jan NEUTZE 17 Dec 2022 16 Dec 2023 Mr Federico PISANI 31 Aug 2022 17 Aug 2023 Ms Miriam Gargesi 09 Aug 2022 05 Aug 2023 Ms Miriam Gargesi 10 Oct 2018 10 Oct 2019 Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
MedTech Europe https://www.medtecheurope.org/
Eucope https://www.eucope.org/
All.Can https://www.all-can.org/Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2020 - Dec 2020
Lobbying costs for closed financial year
75,000€
Other financial info
Illumina receives advice from external public policy consultants. This advice includes planning EU-level outreach initiatives and preparing briefing and position papers.
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
None
Other activities
None declared
Meetings
Meetings
7 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 03 Dec 2021 Location Brussels Subject Presentation of the merger case Illumina and Grail Cabinet Cabinet of Commissioner Elisa Ferreira Portfolio Cohesion and Reforms Attending - Carole Mancel-Blanchard (Cabinet member)
-
Date 03 Dec 2021 Location Brussels, Belgium Subject The public health benefits and competition issues arising out of the merger between Illumina and GRAIL Cabinet Cabinet of Commissioner Janusz Wojciechowski Portfolio Agriculture Attending - Joanna Stawowy (Cabinet member)
-
Date 03 Dec 2021 Location Video-conference Subject Presentation of an early screening test by a cancer screening start-up. Its impact on health, early detection of cancer and especially on most vulnerable groups was discussed in the context of equality policy and the EU Beating Cancer strategy Cabinet Cabinet of Commissioner Helena Dalli Portfolio Equality Attending - Eva Gerhards (Cabinet member)
-
Date 03 Dec 2021 Location Brussels Subject Healthcare benefits of Cancer test Cabinet Cabinet of Vice-President Margaritis Schinas Portfolio Promoting the European Way of Life Attending - Chris Uregian (Cabinet member)
-
Date 03 Dec 2021 Location Virtual Subject Cancer Screening tests, Illumina-GRAIL Merger Cabinet Cabinet of Commissioner Mairead Mcguinness Portfolio Financial services, financial stability and Capital Markets Union Attending - Katherine Power (Cabinet member)
-
Date 12 Nov 2021 Location Videconference Subject Challenges of the health industrial ecosystem Cabinet Cabinet of Commissioner Thierry Breton Portfolio Internal Market Attending - Maurits-Jan Prinz (Cabinet member)
-
Date 29 Sep 2021 Location Brussels (virtual) Subject Illumina/GRAIL transaction, which in addition to important competition policy questions Cabinet Cabinet of President Ursula von der Leyen Portfolio President Attending - Anthony Whelan (Cabinet member)
Other Lobbyists